CAR-T therapy

News

Leschly steps down as 2seventy wields the axe

2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also

Oncology

War in the Blood: The battle takes shape in the burgeoning E...

With the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers

R&D

Oncology R&D hits new heights, but that creates problems

The number of people globally who are being treated for cancer is steadily going up each year.

Oncology

ASCO 2023 – Martin Vogel and Edmond Chan

In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.

News

Trial of 2seventy bio’s AML cell therapy paused after fatali...

Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute

News

J&J builds in CAR-T with $245m Cellular Biomedicine deal

Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil

Leschly steps down as 2seventy wields the axe

War in the Blood: The battle takes shape in the burgeoning E...

Oncology R&D hits new heights, but that creates problems

ASCO 2023 – Martin Vogel and Edmond Chan

Trial of 2seventy bio’s AML cell therapy paused after fatali...

J&J builds in CAR-T with $245m Cellular Biomedicine deal

New UK PM shuts down science and tech department

Discover a new era of healthcare panel engagement: Grounded ...

CAR-T therapy

Editor's Picks